Overview:
In this role you will serve as the local medical voice for AstraZeneca’s Breast Oncology portfolio, shaping a territory-specific medical strategy to improve patient care. You will collaborate with external partners and cross-functional teams to support current products, new indications, and development compounds. You will lead scientific exchanges, gather landscape insights, and help inform R&D and educational efforts. You’ll stay at the forefront of oncology science and contribute to trials and medical operations. This is a high-impact, cross-functional role at the science-to-patient care edge.
Responsibilities:
Serve as the local medical lead to develop and implement a tailored strategy aligned with AZ USMA priorities and local patient needs Build and maintain relationships with academia, hospitals, managed markets, and private practices Lead scientific exchanges with oncologists and MDT members Lead peer-to-peer scientific/medical interactions Gather insights on treatment landscape, healthcare environment, barriers to optimal treatment, and opportunities to improve patient outcomes Discuss data and educational gaps with KOLs to inform RM&D strategy and ensure proper use of medicines Stay current with scientific knowledge and represent the company at relevant meetings and conferences Collaborate with Clinical Operations on trials from feasibility to execution
Key requirements:
Advanced scientific degree (PharmD, MD/DO, PhD, PA or NP) 2+ years of MSL experience or relevant TA experience Proven ability to discuss scientific content to diverse audiences Strong understanding of clinical study design, trial methodology, statistics, and regulatory environment Excellent written and verbal communication; ability to navigate a matrixed environment Strong project management skills Willingness to travel 40–60% (car, train, plane) excellent communication stakeholder relationship-building cross-functional collaboration clinical study design and protocols medical/scientific content expertise in oncology, especially breast cancer regulatory understanding in pharma/biotech